MX2023009623A - Anticuerpos anti-vista y usos de estos. - Google Patents

Anticuerpos anti-vista y usos de estos.

Info

Publication number
MX2023009623A
MX2023009623A MX2023009623A MX2023009623A MX2023009623A MX 2023009623 A MX2023009623 A MX 2023009623A MX 2023009623 A MX2023009623 A MX 2023009623A MX 2023009623 A MX2023009623 A MX 2023009623A MX 2023009623 A MX2023009623 A MX 2023009623A
Authority
MX
Mexico
Prior art keywords
antibodies
vista
vista antibodies
domain
compositions
Prior art date
Application number
MX2023009623A
Other languages
English (en)
Spanish (es)
Inventor
Eric J Tarcha
Shawn P Iadonato
David Scott Johnson
Adam Shultz Adler
Rena Aviva Mizrahi
Michael Asensio
Thierry Guillaudeux
Yoong Wearn Lim
Original Assignee
Kineta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kineta Inc filed Critical Kineta Inc
Publication of MX2023009623A publication Critical patent/MX2023009623A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2023009623A 2021-02-18 2022-02-18 Anticuerpos anti-vista y usos de estos. MX2023009623A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163150995P 2021-02-18 2021-02-18
PCT/US2022/016912 WO2022178203A1 (en) 2021-02-18 2022-02-18 Anti-vista antibodies and uses thereof

Publications (1)

Publication Number Publication Date
MX2023009623A true MX2023009623A (es) 2023-10-23

Family

ID=82931719

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023009623A MX2023009623A (es) 2021-02-18 2022-02-18 Anticuerpos anti-vista y usos de estos.

Country Status (11)

Country Link
US (1) US20240132593A1 (cg-RX-API-DMAC7.html)
EP (1) EP4294530A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024508764A (cg-RX-API-DMAC7.html)
KR (1) KR20230157970A (cg-RX-API-DMAC7.html)
CN (1) CN117177995A (cg-RX-API-DMAC7.html)
AU (1) AU2022223973A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023016533A2 (cg-RX-API-DMAC7.html)
CA (1) CA3208872A1 (cg-RX-API-DMAC7.html)
IL (1) IL305310A (cg-RX-API-DMAC7.html)
MX (1) MX2023009623A (cg-RX-API-DMAC7.html)
WO (1) WO2022178203A1 (cg-RX-API-DMAC7.html)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016332900C1 (en) * 2015-09-29 2024-07-04 Amgen Inc. ASGR inhibitors
PE20250933A1 (es) * 2017-03-14 2025-04-02 Five Prime Therapeutics Inc Anticuerpos de union a vista a ph acido
AU2019301120A1 (en) * 2018-07-11 2021-02-25 Bristol-Myers Squibb Company Antibodies binding to VISTA at acidic pH
WO2020140094A1 (en) * 2018-12-27 2020-07-02 Gigagen, Inc. Anti-b7-h3 binding proteins and methods of use thereof

Also Published As

Publication number Publication date
AU2022223973A1 (en) 2023-09-07
EP4294530A4 (en) 2025-07-16
CA3208872A1 (en) 2022-08-25
JP2024508764A (ja) 2024-02-28
CN117177995A (zh) 2023-12-05
BR112023016533A2 (pt) 2023-11-21
KR20230157970A (ko) 2023-11-17
US20240132593A1 (en) 2024-04-25
EP4294530A1 (en) 2023-12-27
IL305310A (en) 2023-10-01
WO2022178203A1 (en) 2022-08-25

Similar Documents

Publication Publication Date Title
JOP20230312A1 (ar) أجسام مضادة لـ ccr8 واستخداماتها
CL2024003715A1 (es) Proteína de unión multiespecífica que se une a nkg2d, cd33 y cd16; composición; y uso.
CL2022001769A1 (es) Anticuerpos anti-cd73 y usos de estos.
MX2022002682A (es) Anticuerpos anti-cd73.
MX2020012588A (es) Anticuerpos anti-cd33, anticuerpos biespecíficos anti-cd33/anti-cd3 y usos de estos.
EA201992610A1 (ru) Экспансия -t-клеток, композиции и способы их применения
MX2023004869A (es) Anticuerpos contra sars-cov-2 y usos de los mismos.
EA202191785A1 (ru) Антитела к ctla4 и способы их применения
MX394043B (es) Inhibidores de mcl-1 indolicos sustituidos.
CR20220207A (es) Compuestos terapéuticos y métodos de uso
JOP20210164A1 (ar) طرق وتركيبات علاج السرطان
MX2024002391A (es) Inhibidores de indolina de kif18a.
EA201890247A1 (ru) Ингибиторы дезоксиуридинтрифосфатазы, содержащие гидантоин
MX2024003107A (es) Agonistas de ahr.
SA523451582B1 (ar) Ccr8 الأجسام المضادة لـ
MX2022012628A (es) Anticuerpos anti-phf-tau y usos de estos.
EA202092125A1 (ru) Антитела против рецептора фолата 1 и их применения
EA202092695A1 (ru) Композиции, содержащие глюкозу и гемицеллюлозу, и их применение
EA201892500A1 (ru) Применение фракции лигнина в качестве антифитопатогенного агента и содержащие ее антифитопатогенные композиции
PE20230460A1 (es) Anticuerpos anti-cd200r1 y metodos de uso de estos
EA202193296A1 (ru) Конструкции для rnai, предназначенные для подавления экспрессии scap, и способы их применения
MX2023012672A (es) Nuevo anticuerpo anti-vista estable.
MX2021015501A (es) Anticuerpos y metodos de uso.
MX2020013923A (es) Anticuerpos anti molécula de adhesión celular l1 (l1cam) y usos de estos.
WO2020242719A3 (en) Inhibitors of rna-binding proteins, compositions thereof, and therapeutic uses thereof